

CASE CLV-31346A

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450

Sara Carter  
Type or print name

*Sara Carter*  
Signature

July 14, 2003  
Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

LUEKEL ET AL.

APPLICATION NO: 09/802,757

FILED: MARCH 9, 2001

FOR: REACTIVE POLYMERS

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

RECEIVED  
JUL 22 2003  
GROUP 1700

FEE LETTER FOR INFORMATION DISCLOSURE STATEMENT

Sir:

Please charge Deposit Account No. 19-0134 in the name of Novartis in the amount of \$180 for payment of the fee pursuant to 37 CFR §1.17(p) for the submission of an Information Disclosure Statement under 37 CFR §1.97(c).


An additional copy of this paper is here enclosed. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 19-0134 in the name of Novartis.

Respectfully submitted,

*Jian Zhou*

Jian Zhou  
Agent for Applicants  
Reg. No. 41,422

Novartis Pharmaceuticals Corporation  
Patent and Trademark Dept.  
One Health Plaza  
East Hanover, NJ 07936-1080  
(678) 415-4691  
Date: July 14, 2003



CASE CLV-31346A

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450

Sara Carter  
Type or print name

*Sara Carter*  
Signature

July 14, 2003  
Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF  
LUEKEL ET AL.  
APPLICATION NO: 09/802,757  
FILED: MARCH 9, 2001  
FOR: REACTIVE POLYMERS

RECEIVED  
JUL 22 2003  
GROUP 1700

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

This Information Disclosure Statement is being filed in accordance with 37 C.F.R. §1.97(c). A letter for payment of fee set forth in 37 C.F.R. §1.17(p) is enclosed.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

Copies of these references are enclosed herewith.

07/18/2003 SHIKASS1 00000087 190134 09802757

01 FC:1806 180.00 DA

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Novartis Pharmaceuticals Corporation  
Patent and Trademark Dept.  
One Health Plaza  
East Hanover, NJ 07936-1080  
(678) 415-4691

  
Jian Zhou  
Agent for Applicants  
Reg. No. 41,422

Date: July 14, 2003



## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

RECEIVED  
JUL 22 2003  
GROUP 1700

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA	5,002,582	3/26/91	Guire et al.	623	66	12/8/89
	AB	5,512,329	4/30/96	Guire et al.	427	508	12/27/93
	AC	5,582,955	12/10/96	Keana et al.	430	296	6/26/95
	AD	5,741,551	4/21/98	Guire et al.	427	407.1	4/23/96
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AM	EP 0 014 843	1/21/80	EPO			<input type="checkbox"/>	<input type="checkbox"/>
	AN	EP 0 700 932	1/9/95	EPO			<input type="checkbox"/>	<input type="checkbox"/>
	AO	EP 0 764 662	9/7/96	EPO			<input type="checkbox"/>	<input type="checkbox"/>
	AP	GB 0352 149	5/8/74	The Patent Office London			<input type="checkbox"/>	<input type="checkbox"/>
	AQ						<input type="checkbox"/>	<input type="checkbox"/>

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	AR	
	AS	
	AT	

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.